Deborah Dunsire aims for 10 European Vyepti launches this year
![Deborah Dunsire, CEO of Lundbeck | Photo: Gregers Tycho/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13721456.ece/ALTERNATES/schema-16_9/doc7jnduc8dfrq150zfoesy.jpg)
In January, Lundbeck received the much anticipated European approval of migraine drug Vyepti, and the pharmaceutical company has great expectations for the treatment.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck's Northera took massive dive in 2021
For subscribers